Home >> Marketplace Archives >> Lynch syndrome diagnostic tests, 5/14

Lynch syndrome diagnostic tests, 5/14

Print Friendly, PDF & Email

May 2014—Quest Diagnostics is offering new pathology and blood tests for identifying and assessing an individual’s risk of Lynch syndrome.

The guideline-based test services include a comprehensive blood test panel that evaluates MLH1, MSH2 (and EpCAM terminal deletions), MSH6, and PMS2 for inherited mutations responsible for the majority of Lynch syndrome cases. Gene-specific tests are available for those whose family history or tumor tissue results indicate targeting one or more of these genes. The offering also includes a menu of validated biopsy-tumor screening options for patients with a diagnosis of colorectal, endometrial, or other Lynch-associated cancers.

Quest Diagnostics, 973-520-2800


Check Also

Quest acquires two Texas labs, 7/17

July 2017—Quest Diagnostics has signed definitive agreements to acquire Med Fusion and Clear Point, both based in Lewisville, Tex., with the aim to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients nationwide. Baylor Scott & White Health; the US Oncology Network (the Network), supported by McKesson Specialty Health; Texas Oncology; and Pathologists Bio-Medical Laboratories are co-owners of one or both businesses.